June 23, 2016
(Genetic Engineering & Biotechnology News) – Invariably, even medications that have widespread success and effectiveness will often display unpredictable levels of efficacy or adverse drug reactions (ADRs) at some point during clinical administration. Pharmacogenomics is one approach the scientific community uses to address genetic variants among the population related to unwanted and potentially life-threating drug effects. Scientists have attempted to couple drug development with new pharmacogenomic discoveries in an effort to improve current regimens or design new therapeutic strategies.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.